FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Sanofi Pasteur plans C$100M R&D facility in Canada

Tools

Score one win for Ontario province in the field of economic development. Sanofi Pasteur, the vaccine arm of Sanofi-Aventis, will build a C$100 million R&D facility in Toronto with the province chipping in C$13.9 million through its Biopharmaceutical Investment Program.

Researchers will target pediatric combination vaccines, pneumococcal protein vaccines and cancer vaccines. Look for the grand opening in 2010.

- check out the AFX report

Related Articles:
Sanofi licenses technology for new TB vaccine. Sanofi report
Maxygen, Sanofi Pasteur ink $24.5M vaccine deal. Sanofi report
Canada's streamlined approval process raises protests. Canada report
Canada's drug market slowing. Market report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Vaccines   Sanofi Pasteur   Canada   protein   Sanofi